Olema Pharmaceuticals Inc... (OLMA)
5.12
0.28 (5.79%)
At close: Jan 14, 2025, 3:59 PM
5.14
0.39%
Pre-market Jan 15, 2025, 08:31 AM EST
undefined% (undefined)
| Bid | 5 |
| Market Cap | 380.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -2.25 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.24 |
| Volume | 1,183,326 |
| Avg. Volume (20D) | 852,873 |
| Open | 5.44 |
| Previous Close | 4.84 |
| Day's Range | 4.78 - 5.44 |
| 52-Week Range | 4.60 - 16.77 |
| Beta | undefined |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2020
Employees 74
Stock Exchange NASDAQ
Ticker Symbol OLMA
Website https://www.olema.com
Analyst Forecast
According to 5 analyst ratings, the average rating for OLMA stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 427.34% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+0.89%
Olema Pharmaceutical shares are trading higher aft...
Unlock content with
Pro Subscription
